Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06670079 · ClinicalTrials.gov registry record · NA
Prolonged Exposure Therapy to Treat Posttraumatic Stress Disorder in Pregnant Patients
A NA study, sponsored by University of Vermont.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT06670079: Recruiting NA study, sponsored by University of Vermont.
NCT06670079 is a NA study that is actively recruiting participants, run by University of Vermont. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06670079, a NA study, is actively recruiting participants, sponsored by University of Vermont.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if a treatment for adults with PTSD called prolonged exposure + incentives (PE+) works to treat pregnant patients. The main question it aims to answer is: Does PE+ decrease PTSD symptoms? All participants will receive PE+ to see if their PTSD symptoms at the end of the trial are less than at the beginning. Participants will: * Receive individual PE+ therapy for 1 hour weekly for 12 weeks. * Receive financial incentives for attending each PE+ session. * Attend assessment visits every 4 weeks for the 12 weeks of the trial. * Allow research staff to collect some information about their labor and delivery from their medical records after their babies are born.
Primary Outcome
Change in posttraumatic stress disorder symptom severity as measured by Clinician Administered PTSD Scale (CAPS-5) for clinician-rated posttraumatic stress symptoms. The CAPS-5 is a 30-item structured interview. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 PTSD symptoms, each with severity scores ranging from 0-4. The overall total severity score for CAPS-5 ranges from 0-80, with lower scores representing better outcomes (less severe PTSD).
Interventions
- BEHAVIORAL Prolonged exposure therapy + incentives for therapy session attendance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-02-05 |
| Est. Completion | 2027-07-22 |
| Phase | NA |
What NCT06670079 shows while recruiting
NCT06670079 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Prolonged exposure therapy + incentives for therapy session attendance is the first listed.
NCT06670079 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06670079 about?
NCT06670079 is a clinical study titled "Prolonged Exposure Therapy to Treat Posttraumatic Stress Disorder in Pregnant Patients". The goal of this clinical trial is to learn if a treatment for adults with PTSD called prolonged exposure + incentives (PE+) works to treat pregnant patients. The main question it aims to answer is: Does PE+ decrease PTSD symptoms? All participants will receive PE+ to see if their PTSD symptoms at...
What is the current status of trial NCT06670079?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2026-02-05. Estimated completion is 2027-07-22.
What interventions are being tested in trial NCT06670079?
The interventions under investigation include: Prolonged exposure therapy + incentives for therapy session attendance (BEHAVIORAL).
Who is sponsoring clinical trial NCT06670079?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06670079's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI